2018 Summary: The Status and Future of Products in China's Anti-Infection Field

the original title: 2018 summary: China's anti-infection field of products and the future of theaccording to the rice data, systemic anti-infective drugs are the largest market share of the chemical drug market drug category, representing products have cephalosporine, penicillin and carbon penicillinIn 2017, the total market size of systemic anti-infective drugs was RMB169 billion, accounting for 18.69 percent of the chemical marketThis was followed by the digestive metabolism and blood hematopoietic systems, which accounted for 16.62% and 12.93% of the market, respectivelyin the whole body with anti-bacterial drugs, TOP3 anti-infective drugs, accounting for more than 70% of the market shareThese three categories arecephalosporine, penicillin
andcarbon penicillinAmong them, the market size of the first head spores antibacterial drugs, but also accounted for more than half of the antimicrobial marketwith the development of consistency evaluation, the market pattern in the field of anti-infection is also quietly changingEspecially in the context of national band procurement, the role of pharmaceutical marketing is gradually weakenedThe progress of consistency evaluation becomes a key factor in determining market sharebelow, the progress of consistency evaluation is used to analyze possible changes in the field of antibiotics in the futureAs far as the current market is concerned, the first class of antibiotic products is not cephalosporineCephalospore products can be roughly divided into 5 generations, 5 generations of cephalosporine have their own characteristicsWith the continuous improvement of cephalosporine products, the toxic side effects of this product are getting smaller and smaller, acid-resistant and enzyme-resistant, and the field of treatment is becoming more and more extensiveAs a result, it has gradually become the mainstream of the field of anti-infection, cephalosporine
Through the progress of the reference preparation filing and consistency evaluation, it can be assumed that Qilu Pharmaceuticals will lead the way in the field of cephalosporineAt present, Qilu already has two cephalosporine products in the review and approval stage of the conformity evaluation: they are injected with cephalosporine and injection of sodium pentacephalosporineIn addition, products that have been filed with the reference preparation include sodium cephalosporine for injection and sodium cephalosporine for injectionIf the consistency evaluation is successfully completed, Qilu will also have a market share impact on the productThe market size of these four products alone is more than 16 billion yuanThe average market size of a single product is more than 4 billion yuanII, penicillin
In the field of penicillin, as the eldest son of the Republic's pharmaceutical class, North China Pharmaceuticals still shows a strong market advantageHowever, North China Pharmaceuticals, which is home to its eldest son, does not seem to have kept pace with the Republic's growthIn the record of the reference preparation, the top ten penicillin products sold did not see the figure of North China PharmaceuticalsIn contrast, three of the four dominant products of North China Pharmaceuticals have been overtaken by Qilu in the consistency evaluationI believe that with the promotion of consistency evaluation, supporting the bidding and procurement policy, North China Pharmaceutical market will gradually be replaced by QiluIII, carbon amycin
Carbon amyno compounds, because of the usual amorphous structure of penicillin significantly different, so that it has a very broad spectrum, very strong antibacterial activity, as well as beta-lactamase high stability Carbon penicillin products are also known as the most extensive antibacterial spectrum, antibacterial activity of the strongest atypical beta-lactam antibiotics but because of its novel structure, the latest time to enter China, domestic pharmaceutical companies in this kind of drugs and foreign pharmaceutical companies are the most gap As a result of the market, most of these products are occupied by foreign pharmaceutical companies Even in the work of consistency evaluation, the participation of domestic pharmaceutical companies is not high so far, no domestic company has shown an advantage in carbon-amylen products Therefore, the pattern of such products will not change for a short time fourth, summary in the total forest chemical products, anti-infective drugs play an obscure but very important role In the field of anti-infection battlefield, is roughly a three-way pattern The three categories of products are cephalosporine, penicillin and carbon penicillin, among which, carbon penicillin because of novel structure, into China late, so the existing enterprises have a first-mover advantage It also means that the existing pattern is difficult to break In cephalosporine and penicillin products, Qilu has not shown strong market dominance at present, but with the consistency evaluation, Qilu's potential will be fully released Especially in the context of national volume procurement, marketing function weakened, early adoption of consistency evaluation means early market grabbing, or even the completion of market replacement reference: NMPA/CDE; Mine; Pharmaceutical Melt data, Pharnex Datamonitor; Pharmaceutical Ring; FDA/EMA; Public Disclosure of Related Companies, etc